SINDRONAT 300mg / 5ml perfusive solution concentrate medication leaflet

M05BA02 clodronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates

Clodronic acid is a bisphosphonate used to treat osteoporosis and hypercalcemia associated with bone metastases. It helps reduce bone loss by inhibiting osteoclast-mediated bone resorption.

It is commonly used in the treatment of cancer patients with bone metastases, helping to reduce pain and the risk of fractures. It can also be used to treat malignant hypercalcemia, a condition characterized by high calcium levels in the blood.

Clodronic acid is administered either orally or intravenously, depending on the medical indication. Side effects may include nausea, diarrhea, and, in rare cases, impaired kidney function. It is important for patients to strictly follow their doctor's recommendations to minimize risks.

Patients using clodronic acid should be periodically monitored to assess kidney function and blood calcium levels. It is contraindicated in cases of severe renal impairment.

General data about SINDRONAT 300mg / 5ml

Substance: clodronic acid

Date of last drug list: 01-06-2025

Commercial code: W52199001

Concentration: 300mg / 5ml

Pharmaceutical form: perfusive solution concentrate

Quantity: 1

Product type: generic

Price: 52.79 RON

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.

Marketing authorisation

Manufacturer: SINDAN-PHARMA S.R.L. - ROMANIA

Holder: TEVA B.V. - OLANDA

Number: 9261/2016/01

Shelf life: 3 years

Pharmaceutical forms available for clodronic acid

Concentrations available for clodronic acid

300mg/5ml, 400mg, 60mg/ml, 800mg

Compensation lists for SINDRONAT 300mg / 5ml ACTAVIS

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

52.79 RON

52.79 RON

0.00 RON